Ablatherm® HIFU clinical publications
2008 – 03 : First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer
Andreas Blana et al. 2007 European Urology 2271 article in press
"This study demonstrates the effective long-term cancer control achieved using HIFU in patients with low- or intermediate-risk localised prostate cancer. We belived HIFU provides a potential treatment option for localised prostate cancer in patients who are not eligible for surgery. The additional benefit of a favourable morbidity profile should persuade clinicians to consider more patients for this curative option, which is, in our opinion, a valid alternative to radiotherapy."
2008 – 02 : High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology
Xavier Rebillard**Clinique Beau Soleil, Montpellier et al. BJU International 2008 1464-410X.2008.07504.x
"In patients selected [...], HIFU results in short-term cancer control, as shown by a high percentage of negative biopsies and substantially decreased PSA levels. Median-term DFS data (with the Ablatherm device) seem promising. With the continuous development of the Ablatherm device and the use of TURP before HIFU, the rate of HIFU-related complications has decreased. Recent studies show that HIFU is well tolerated, with a low rate of complications that compare favourably with those after established therapies. Longer-term follow-up studies are needed to further evaluate cancer-specific and overall survival rates."
2008 - 01 : Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer
François-Joseph Murat et al. 2008 European Urology, doi:10.1016/j.eururo.2008.04.091
"Salvage HIFU is a promising treatment option for local relapse after RT failure. This retrospective analysis shows high local tulour control. Favourable 5-yr outcomes are expected if HIFU is performed for low-risk or intermediate-risk patients. There are acceptable morbidity rates and especially nu URF with the specific post-radiation parameters. [...] Future advances in technology and safety will undoubtely expand the HIFU role in this indication.
2007 – 01 : Factors Predicting for Formation of Bladder Outlet Obstruction After High-Intensity Focused Ultrasound in Treatment of Localized Prostate Cancer
Andreas Blana et al. 2007 Journal of Urology 2007.12.076 Article in Press
"In our study, the occurrence of BOO after HIFU was significantly associated statistically with older age. Surprisingly, TURP before HIFU was not an independent factor in the prevention of BOO during follow-up. However, the occurence of multiple BOO episodes could be reduced by resecting more tissue with TURP before HIFU."
2006 – 07 : High Intensity Focused Ultrasound for Prostate Cancer: A Review of the Scientific Foundation, Technology and Clinical Outcomes
John C. Rewcastle, Ph.D., Department of Radiology, University of Calgary, Canada
Technology in Cancer Research and Treatment, Vol. 5, Number 6, December 2006, 619-625
"High intensity focused ultrasound is a technologically advanced non-invasive therapy for prostate cancer. There currently exist two commercially available treatment units each with their own merits. Longer follow-up is available with the Ablatherm device, which also has demonstrated high local disease control in multicenter investigations. The role of HIFU will continue to be defined as more patient series are published with longer term follow-up."
2006 – 06 : Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer
Vincenzo Ficarra, 2006 BJU International, 98, 1193-1198
"HIFU is a minimally invasive therapy for prostate cancer ofter used in selected patients with localized disease. The present results showed that HIFU combined with adjuvant pharmacological castration was feasible also in patients with high-risk prostate cancer. The low complication rates, favourable functional outcome and particularly the promising preliminary oncological data support the planning of further larger studies in such patients. The oncological efficacy of the present protocol should be assessed in further studies with more patients and a longer follow-up."
2006 – 05 : Recurrent Prostate Cancer After Radiotherapy – Salvage Treatment by High Intensity Focused Ultrasound
F-J. Murat,L. Poissonnier, A. Gelet, Hôpital Edouard Herriot, Lyon, France European Oncological Disease, Sept. 2006, 64-66
"Treatment with HIFU allowed local tumour control in 84% of patients treated for prostate cancer recurrence after radiotherapy, but disease control depended on initial risk factor and Gleason score at the time of recurrence. High-risk patients (T3 or PSA >20 or Gleason score ≥8) are not good candidates for salvage treatment with HIFU: they must be strictly selected (18F-fluorocholine PET scan) as the majority have silent metastases associated with local recurrence. Conversely, treatment with HIFU is a very interesting curative option for low- or intermediate-risk patients, particularly if the Gleason score of the local recurrence is ≤7."
2006 – 04 : Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Laura Poissonnier. Eur Urol. 2006 May 2
"Transrectal HIFU is a minimally invasive therapy that controled localized prostate cancer locally in 86% of the cases. This therapy provided disease control in 66% of the patients with clinically confined prostate cancer. Early feedback on treatment efficacy was gained by using nadir PSA (obtained within 4 months) and random control biopsies."
2006 – 03 :High-intensity focused ultrasound therapy for clinically localized prostate cancer
HM Lee, JH Hong and HY Choi. Prostate Cancer and Prostatic Diseases (2006), 1-5 .
2006 – 02 : Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer
Andreas Blana, Sebastian Rogenhofer, Roman Ganzer, Peter J. Wild, Wolf F. Wieland, Bernhard Walter. World J Urol. 2006 Jul 19
"Additional HIFU treatments in case of primary treatment failure for patients with localized prostate cancer are associated with only a minor increase in morbidity.However the forthcoming aim will be to lower the rate of patients with residual cancer after initial HIFU treatment by refined patient selection and more effective treatment modalities."
2006 – 01 : HIFU: Local Treatment of Prostate Cancer
H. Azzouz, J.J.M.C.H. de la Rosette. EAU-EBU update series 4, 2006, 62-70
"HIFU has proven mid-term high local and biochemical efficacy in patients with local confined prostate cancer. A HIFU also shows promising results in local recurrence of prostate cancer after external beam radiation."
2005 – 03 : Treatment of Localised Prostate Cancer with Transrectal High-intensity Focused Ultrasound
G. Vallacien
European Kidney & Urological Disease, Nov. 2005, 61-62
2005 – 02 : Transrectal High Intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer
X. Rebillard (1), A. Gelet (2), J.L. Davin (3), M. Soulie (4), D. Prapotnich (5), X. Cathelineau (5), F. Rozet (5), G. Vallancien (5). (1) Clinique Beau Soleil, Montpellier, France, (2) Dpt of Urology, Edouard Herriot Hospital, Lyon, France, (3) Clinique Rhône Durance, Avignon, France, (4) CHU Rangueil, Toulouse, France, (5) Institut Mutualiste, Paris, France.
Journal of Endourology, Vol. 19, No. 6, p. 693-701, July/August 2005
2005 – 01 : Technology Insight: High Intensity Focused Ultrasound for Urologic Cancers
C. Chaussy (1), S. Thüroff (1), X. Rebillard (2), A. Gelet (3). (1) Dpt of Urology, University Hospital of Munich-Harlaching, Germany. (2) Clinique Mutualiste Beausoleil, Montpellier, France. (3) Dpt of Urology, Edouard Herriot Hospital, Lyon, France.
NATURE Clinical Practice Urology, Vol. 2, No. 4, p. 191-198, April 2005
2004 – 02 : Local Recurrence of Prostate Cancer after External Beam Radiotherapy: Early Experience of Salvage Therapy using High-Intensity Focused Ultrasonography
A. Gelet, J.Y. Chapelon, L. Poissonnier, R. Bouvier, O. Rouvière, L. Curiel, M. Janier, G. Vallancien, Hôpital Edouard Herriot, Dept. of Urology, Lyon, Institut Montsouris, Dept. of Urology, Paris, France.
Urology 63 (4), p. 625-629, April 2004
2004 – 01 : High Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: 5-year Experience
A. Blana, B. Walter, S. Rogenhofer, W.F. Wieland, University of Regensburg, Dept. of Urology, Germany.
Urology 63 (2), p. 297-300, 2004
2003 – 02 :High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study
S. Thüroff(1), C. Chaussy (1), G. Vallancien (2), W. Wieland (3), H.J. Kiel (3), A. Le Duc (4), F. Desgrandchamps (4), J. De La Rosette (5), A. Gelet (6). Munich-Harlaching University, München, Germany (1) - Institut Mutualiste Montsouris, Paris, France (2) - Caritas Krankenhaus, Regensburg, Germany (3) - Hôpital Saint-Louis, Paris, France (4) - University Medical Center St Radboud, Nijmegen, The Netherlands (5) - Hôpital Edouard Herriot, Lyon, France (6).
Journal of Endourology, Volume 17, Number 8, October 2003
2003 – 01 : The Status of High-Intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer and the Impact of a Combined Resection
C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany.
Current Urology Reports, Volume 4, Issue 3, 2003
2001 – 01 : Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Factors Influencing the Outcome
A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France.
European Urology, 2001; 40:124-129
2000 – 01 : Transrectal High-Intensity Focused Ultrasound: Minimally Invasive Therapy of Localized Prostate Cancer
A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, Y. Lasne, D. Lyonnet, J.M.Dubernard. Edouard Herriot Hospital, Lyon, France.
Journal of Endourology, Volume 14, Number 6, August 2000
